Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02156570




Registration number
NCT02156570
Ethics application status
Date submitted
3/06/2014
Date registered
5/06/2014
Date last updated
21/09/2018

Titles & IDs
Public title
DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)
Scientific title
An Interferon Sparing Strategy of Sofosbuvir Plus Ribavirin for the Treatment of Recently Acquired Hepatitis C Infection
Secondary ID [1] 0 0
VHCRP1206
Universal Trial Number (UTN)
Trial acronym
DARE-C II
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis C 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Sofosbuvir and ribavirin

Experimental: Sofosbuvir and ribavirin - Sofosbuvir tablet 400 mg daily Ribavirin tablet weight based dosing (1000mg <75 kg, 1200mg >/= 75kg) daily
Treatment will be for 6 weeks in all participants.


Treatment: Drugs: Sofosbuvir and ribavirin
Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg <75kg, 1200mg >/= 75 kg) Treatment will be for 6 weeks in all participants.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
SVR 12
Timepoint [1] 0 0
12 weeks post treatment
Secondary outcome [1] 0 0
SVR 24
Timepoint [1] 0 0
24 weeks post treatment

Eligibility
Key inclusion criteria
- Provision of written informed consent

- Male and female patients aged 18 years and above

- Willing to use two effective methods of contraception during the treatment period and
24 weeks post.

- HBsAg negative

- Detectable HCV RNA at screening (>10,000 IU/ml), and in the opinion of the
investigator is unlikely to demonstrate spontaneous viral clearance

- Compensated liver disease (Child-Pugh A)

- Negative pregnancy test at screening and 24 hours prior to first dose of study drugs

- Medically stable on the basis of physical examination, medical history and vital signs

- Adequate English to provide reliable responses to the study questionnaires

- Recent hepatitis C infection, as defined by: A) i) First anti-HCV Ab or HCV RNA
positive within the previous 6 months and ii) Documented anti-HCV Ab negative within
the 24 months prior to anti-HCV antibody positive result, OR B) i) First anti-HCV Ab
or HCV RNA positive within the previous 6 months and ii) acute clinical hepatitis
(jaundice or ALT> 10 X ULN) within the previous 12 months prior to first positive HCV
antibody or HCV RNA, with no other cause of acute hepatitis identifiable

If co-infection with HIV is documented, the subject must meet the following criteria:

- Antiretroviral (ARV) untreated for >8 weeks preceding screening visit with CD4 T cell
count >500 cells/mm3 OR

- On a stable ARV regimen for >8 weeks prior to screening visit, with CD4 T cell count
>200 cells/mm3 and an undetectable plasma HIV RNA level.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Standard exclusions to RBV therapy

- Pregnancy/lactation or male subjects whose female partners are pregnant

- Subject has a history of decompensated liver disease: history of ascites, hepatic
encephalopathy, or bleeding oesophageal varices, and/or any of the following screening
laboratory results: a.INR of =1.5; Serum albumin <3.3 g/dL; Serum total bilirubin >1.8
times upper limit of normal, unless isolated in subjects with Gilbert's syndrome.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2017
Sample size
Target
20
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
St Vincent's Hospital - Sydney
Recruitment hospital [2] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [3] 0 0
Alfred Hospital - Melbourne
Recruitment hospital [4] 0 0
Royal Melbourne Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2010 - Sydney
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment postcode(s) [4] 0 0
3050 - Melbourne
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Grafton

Funding & Sponsors
Primary sponsor type
Other
Name
Kirby Institute
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to examine whether patients who have acute or early chronic
hepatitis C virus (HCV) infection can be treated effectively and safely with an
interferon-sparing regimen that combines a new direct acting antiviral drug (sofosbuvir) with
one of the standard treatments for chronic hepatitis C (ribavirin). In particular, this study
will investigate whether treatment of acute or early chronic HCV can be shortened. The study
will assess efficacy by looking at the proportion of people who clear the virus (have no
virus detectable in their blood) at the end of treatment, and 1, 3 and 6 months after
treatment.

The hypothesis is that short course (6 weeks) dual therapy using sofosbuvir and RBV will
result in successful virological eradication in the majority (=80%) of subjects treated for
recently acquired HCV.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02156570
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Gail Matthews, MbChB FRACP
Address 0 0
Kirby Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02156570